Bleeding Time and Platelet Function in Essential Thrombocythemia and Other Myeloproliferative Syndromes

References

• Murphy S., Iland H., Rosenthal D., Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin. Hematol. 1986; 23: 177–182
   PubMed Web of Science ®Google Scholar
• Iland H., Laszlo J. Myeloproliferative-related thrombocytosis: clinical significance and comparison with other causes of thrombocytosis. Medical Grand Rounds 1984; 3(3)225–38
   Google Scholar
• Michiels J. J., Prins M. E., Hagermeijer A., Brederoo P., van der Meulen J., van Vliet H. H. D.M., Abels J. Philadelphia chromosome-positive thrombocythemia and megakaryoblastic leukemia. Am. J. Clin. Pathol. 1987; 88: 645–52
   PubMed Web of Science ®Google Scholar
• van Genderen P. J. J., Michiels J. J. Primary thrombocytemia: diagnosis, clinical manifestations and management. Ann. Hematol. 1993; 67: 57–62
   PubMed Web of Science ®Google Scholar
• Roznan C., Giralt M., Feliu E., et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658–2663
   PubMed Web of Science ®Google Scholar
• Michiels J. J., Abels J., Steketee J., van Vliet H. H. D.M., Vuzevski V. D. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann. Intern. Med. 1985; 102: 466–471
   PubMed Web of Science ®Google Scholar
• Budde U., Schaefer G., Mueller N., Egli H., Dent J., Ruggeri Z. M., Zimmerman T. S. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64: 981–985
   PubMed Web of Science ®Google Scholar
• Ivy A. C., Nelson D., Bucher G. The standardization of certain factors in the cutaneous “venostasis” bleeding time technique. J. Lab. Clin. Med. 1941; 26: 1812–1822
   Google Scholar
• Mielke C. H., Kaneshiro M. M., Maher I. A., Weiner J. M., Rapaport S. I. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204–215
   PubMed Web of Science ®Google Scholar
• Channing Rodgers R. P., Levin J. A critical reappraisal of the bleeding time. Semin. Thromb. Haemostas. 1990; 16: 1–20
   Web of Science ®Google Scholar
• Coller B. S. von Wiliebrand disease. Hemostasis and Thrombosis. Basic principles and clinical practice, R. W. Colman, J. Hirsh, V. J. Marder, E. W. Salzman. Lippincott, Philadelphia, PA 1987; 60–96
   Google Scholar
• Abildgaard C. F., Suzuki Z., Harrison J., Iefcoat K., Zimmerman T. S. Serial studies in von Willebrand's disease: variability versus “variants”. Blood 1980; 56: 712
   PubMed Web of Science ®Google Scholar
• Lind S. E. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547–2552
   PubMed Web of Science ®Google Scholar
• De Caterina R., Lanza M., Manca G., Buti Strata G., Maffei S., Salvatore L. Bleeding time and bleeding: an analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood 1994; 84: 3363–3370
   PubMed Web of Science ®Google Scholar
• Bellucci S., Janvier M., Tobelem G., Flandrin G., Charpak Y., Berger R., Boiron M. Essential thrombocythemia: Clinical evolutionary and biological data. Cancer 1986; 58: 2440–2447
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Jahn M., Baumann B., Kopcke W. Essential thrombocthemia: Clinical characteristics and course of 61 cases. Cancer 1988; 61: 2487–2496
   PubMed Web of Science ®Google Scholar
• Fenaux P., Simon M., Caulier M. T., Lai J. L., Goudemand J., Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549–556
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Viero P., Finazzi G., D'Emilio A., Rodeghiero F., Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol. 1990; 8: 556–562
   PubMed Web of Science ®Google Scholar
• Mitus A. J., Barbui T., Shulman L. N., Rosenthal D. S., Viero P., Cortelazzo S., Schafer A. I. Hemostatic complications in young patients with essential thrombocythemia. Am. J. Med. 1990; 88: 371–375
   PubMed Web of Science ®Google Scholar
• Colombi M., Radaelli F., Zocchi L., Maiolo A. T. Thrombotic and hemorrhagic complications in essential thrombocytopenia. Cancer 1991; 67: 2926–2930
   PubMed Web of Science ®Google Scholar
• Didesheim P., Bunting D. Abnormal platelet function in myelofibrosis. Am. J. Clin. Pathol. 1996; 45: 566–573
   Google Scholar
• Zucker S., Mielke C. H. Classification of thrombocytosis based on platelet function tests: Correlation with hemorrhagic and thrombotic complications. J. Lab. Clin. Med. 1972; 80: 385–394
   PubMedGoogle Scholar
• Berger S., Aledort L. M., Gilbert H. S., Hanson J. P., Wasserman L. R. Abnormalities of platelet function in patients with polycythemia vera. Cancer Res. 1973; 33: 2683
   PubMed Web of Science ®Google Scholar
• Barbui T., Cortelazzo S., Viero P., BassanDini R., Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function. Eur. J. Cancer Clin. Oncol. 1983; 19: 1593–1599
   PubMedGoogle Scholar
• Murphy S., Davis J. L., Walsh P., Gardner F. H. Template bleeding time and clinical hemorrhage in myeloproliferative disease. Arch. Intern. Med. 1978; 138: 1251–1253
   PubMed Web of Science ®Google Scholar
• Viero P., Buelli M., Comotti B., Minetti B., Cortelazzo S., Barbui T. Prednisone corrects the prolonged bleeding time in thrombocythemia. Thromb. Haemostas. 1988; 47: 188
   Google Scholar
• van Genderen P. J. J., Michiels J. J., Vliet H. H. D.M. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann. Hematol. 1994; 69: 81–84
   PubMed Web of Science ®Google Scholar
• Barbui T., Bassan R., Viero P., Cortelazzo S., Dini E. Platelet function after busulphan in chronic myeloproliferative disorders. Haematologica 1983; 68: 469–477
   PubMedGoogle Scholar
• Pareti F. I., Gugliotta L., Mannucci L., Guarini A., Mannucci P. M. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb. Haemost. 1982; 47: 84–89
   PubMed Web of Science ®Google Scholar
• Schafer A. I. Bleeding and thrombosis in myeloproliferative disorders. Blood 1984; 64: 1–12
   PubMed Web of Science ®Google Scholar
• Gunz F. W. Hemorrhagic thrombocythemia. A critical review. Blood 1960; 15: 705–23
   Google Scholar
• van Genderen P. J. J., Michiels J. J. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythemia. Presse. Med. 1994; 23: 73–77
   PubMed Web of Science ®Google Scholar
• Budde U., Scharf R. E., Franke P., Hartmann-Budde K., Dent J., Ruggeri Z. M. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 1749–1757
   PubMed Web of Science ®Google Scholar
• Lopez-Fernandez M. F., Lopez-Berges C., Martin R., Pardo A., Ramos F. J., Batlle J. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thromb. Haemostas. 1987; 58: 753–757
   PubMed Web of Science ®Google Scholar
• Malpass T. W., Savage B., Hanson S. R., Slichter S. J., Harker L. A. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J. Lab. Clin. Med. 1984; 103: 894–904
   PubMed Web of Science ®Google Scholar
• Lofvenberg E., Nilsson T. K. Qualitative platelet defects in chronic myeloproliferative disorders—evidence for reduced ATP secretion. Eur. J. Haematol. 1989; 43: 435–440
   PubMed Web of Science ®Google Scholar
• Barbui T., Buelli M., Cortelazzo S., Viero P., De Gaetano G. Aspirin and risk of bleeding in patients with thrombocythemia. Am. J. Med. 1987; 83: 265–68
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Orlando E., Barbui T. Defective platelet thromboxane A2 (TXA2), 12-hydroxyeicosatetranoic acid (12-HETE) synthesis, and abnormal platelet function in essential thrombocythemia. Thromb. Haemostas 1989; 62((Suppl.))311, (abstr.)
   Google Scholar
• Buchanan M. R., Butt R. W., Hirsh J., Markham B. A., Nazir D. J. Role of lipooxygenase metabolism in platelet function: effect of aspirin and salicylate. Prostaglandins Leukotriens. Med. 1986; 21: 157–168
   PubMed Web of Science ®Google Scholar
• Schafer A. I. Deficiency of platelet lipooxygenase activity in myeloproliferative disorders. N. Engl. J. Med. 1982; 306: 381–386
   PubMed Web of Science ®Google Scholar
• Baker R. I., Manoharan A. Platelet function in myeloproliferative disorders: Characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur. J. Haematol. 1988; 40: 267–272
   PubMed Web of Science ®Google Scholar
• Balduini C. L., Bertolino G., Noris P., Piletta G. C. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am. J. Clin. Pathol. 1991; 95: 82–86
   PubMed Web of Science ®Google Scholar
• Baumann B., Hillmer I., Hehlmann R. Untersuchungen zur Thrombozytenfunktion bei essentieller Thrombozythämie und reaktiver Thrombozytose. Klin. Wochenschr. 1988; 66: 199–207
   PubMedGoogle Scholar
• Boneu B., Nouvel C., SieCaranobe P., Combes D., Laurent G., Paris J., Bierme J. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests. Scand. J. Haematol. 1980; 25: 214–220
   PubMedGoogle Scholar
• Tangun Y. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders. Thromb. Diath. Hemorrh. 1971; 25: 241–51
   PubMedGoogle Scholar
• Ginsburg A. D. Platelet function in patients with high platelet counts. Ann. Intern. Med. 1975; 82: 506–11
   PubMed Web of Science ®Google Scholar
• Cooper B., Schafer A. I., Puchalsky D., Handin R. I. Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders. Blood 1978; 52: 618–626
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Barbui T., Bassan R., Dini R. Abnormal aggregation and increased size of platelets in myeloproliferative disorders. Thromb. Haemostas. 1980; 43: 127–130
   PubMed Web of Science ®Google Scholar
• Fabris F., Randi M., Casonato A., Girolami A. The possible value of platelet aggregation studies in patients with increased platelet number. Blut. 1981; 43: 279–285
   PubMedGoogle Scholar
• Handa M., Watanabe K., Kawai Y., Kamata T., Koyama T., Nagai H., Ikeda Y. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (α2β1 integrin) deficiency associated with a myeloproliferative disorder. Thromb. Haemostas. 1995; 73: 521–528
   PubMed Web of Science ®Google Scholar
• Kaywin P., McDonough M., Insel P. A., Shattil S. Platelet function in essential thrombocythemia: Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N. Engl. J. Med. 1978; 299: 505–509
   PubMed Web of Science ®Google Scholar
• Nishimura J., Okamoto S., Ibayashi H. Abnormalities of platelet adenine nucleotides in patients with myeloproliferative disorders. Thromb. Haemostas. 1979; 41: 787–795
   PubMed Web of Science ®Google Scholar
• Neemeh J. A., Bowie E. J. W., Thompson J. H., Didisheim P., Owen C. A. Quantitation of platelet aggregation in myeloproliferative disorders. Am. J. Clin. Pathol. 1972; 57: 336–47
   PubMed Web of Science ®Google Scholar
• Sehayek E., Ben-Yousef N., Modan M., Chetrit A., Meytes D. Platelet parameters and aggregation in essential and reactive thrombocytosis. Am. J. Clin. Pathol. 1988; 90: 431–436
   PubMed Web of Science ®Google Scholar
• Ushikubi F., Okuma M., Ishibashi T., Narumiya S., Uchino H. Deficient elevation of the cytoplasmic calcium ion concentration by epinephrine in epinephrine-insensitive platelets of patients with myeloproliferative disorders. Am. J. Hematol. 1990; 33: 96–100
   PubMed Web of Science ®Google Scholar
• Wehmeier A., Scharf R. E., Fricke S., Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders—relation of platelet disorders to clinical aspects of the disease. Haemostasis 1989; 19: 251–259
   PubMedGoogle Scholar
• Wehmeier A., Scharf R. E., Fricke S., Schneider W. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur. J. Haematol. 1990; 45: 191–197
   PubMed Web of Science ®Google Scholar
• Wehmeier A., Tschope D., Esser J., Menzel C., Nieuwenhuis H. K., Schneider W. Circulating activated platelets in myeloproliferative disorders. Thrombos. Res. 1991; 61: 271–278
   PubMed Web of Science ®Google Scholar
• Adams T., Schutz L., Goldberg L. Platelet function abnormalities in the myeloproliferative disorders. Scand. J. Haematol. 1974; 13: 215–24
   PubMedGoogle Scholar
• Zahavi J., Zahavi M., Firsteter E., Frish B., Turleanu R., Rachmani R. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur. J. Haematol. 1991; 47: 326–332
   PubMed Web of Science ®Google Scholar
• Russell N. H., Salmon J., Keenan J. P., Bellingham A. J. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb. Res. 1981; 22: 389–97
   PubMed Web of Science ®Google Scholar
• Wu K. K. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann. Intern. Med. 1978; 88: 7–11
   PubMed Web of Science ®Google Scholar
• Vreeken J., Van Aken W. G. Spontaneous aggregation of blood platelets in a case of idiopathic thrombosis and recurrent painful toes and fingers. Lancet 1971; 2: 1394–7
   Web of Science ®Google Scholar
• van Genderen P. J. J., Michiels J. J., Zijlstra F. J. Lypoxygenase deficiency in primary thrombocythemia is not a true deficiency. Thromb. Haemostas 1994; 71: 803–4
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Galli M., Castagna D., Viero P., De Gaetano G., Barbui T. Increased response to arachidonic acid and U-46619 in patients with chronic myeloproliferative disorders. Thromb. Haemostas. 1988; 59: 73–76
   PubMed Web of Science ®Google Scholar
• Ushibuki F., Okuma M., Kanaji K., Sugiyama T., Ogoroschi T., Narumiya S., Uchino H. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity. Thromb. Haemostas. 1987; 57: 158–64
   PubMed Web of Science ®Google Scholar
• Viero P., Cortelazzo S., Bassan R., Barbui T. Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases. Thromb. Haemostas. 1982; 48: 125–126
   PubMed Web of Science ®Google Scholar
• Grossi A., Vannucchi A., Rafanelli D., Filimberti E., Ferrini P. R. Beta-thromboglobulin content in megacariocytes of patients with myeloproliferative diseases. Thromb. Res. 1986; 43: 367–374
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Viero P., Barbui T. Platelet activation in myeloproliferative disorders. Thromb. Haemostas. 1981; 45: 211–213
   PubMed Web of Science ®Google Scholar
• Dudley J. M., Messinezy M., Eridani S., Holland L. J., Lawrie A., Nunan T. O., Sawyer B., Savidge G. F., Pearson T. C. Primary—thrombocythaemia Diagnostic criteria and a simple scoring system for positive diagnosis. Br. J. Haematol. 1989; 71: 331–335
   PubMed Web of Science ®Google Scholar
• Leoncini G., Maresca M., Buzzi E., Piana A., Armani U. Platelets of patients affected with essential thrombocythemia are abnormal in plasma membrane and adenine nucleotide content. Eur. J. Haematol. 1990; 44: 115–119
   Web of Science ®Google Scholar
• Caranobe C., Sie P., Nouvel C., Laurent G., Pris J., Boneu B. Platelets in myeloproliferative disorders II. Serotonin uptake and storage: Correlations with mepacrine labelled dense bodies and with platelet density. Scand. J. Haematol. 1980; 25: 289–295
   PubMedGoogle Scholar
• Cortelazzo S., Viero P., Buczko W., Barbui T., De Gaetano G. Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders. Scand. J. Haematol. 1985; 34: 146–151
   PubMedGoogle Scholar
• Eche N., Caranobe C., Nouvel C., Pris J., Boneu B. Platelets in myeloproliferative disorders III. Glycoprotein profile in relation to platelet function and platelet density. Scand. J. Haematol. 1981; 26: 123–9
   PubMedGoogle Scholar
• Bolin R. B., Okumura T., Jamieson G. A. Changes in distribution of platelet membranes glycoproteins in patients with myeloproliferative disorders. Am. J. Hematol. 1977; 3: 63–71
   PubMed Web of Science ®Google Scholar
• Mazzucato M., De Marco L., De Angelis V., Deroia D., Bizzaro N., Casonato A. Platelet membrane abnormalities in myeloproliferative disorders—decrease in glycoprotein-IB and glycoprotein-IIb/IIIa-complex is associated with deficient receptor function. Br. J. Haematol. 1989; 73: 369–374
   PubMed Web of Science ®Google Scholar
• Clezardin P., McGregor P. L., Dechevanne M., Clementson M. C. Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. Br. J. Haematol. 1985; 60: 331–344
   PubMed Web of Science ®Google Scholar
• Misty R., Cahill M., Chapman C., Wood J. K., Barnett K. D. 125-I-fibrinogen binding to platelets in myeloproliferative disease. Thromb. Haemostas. 1991; 66: 329–333
   PubMed Web of Science ®Google Scholar
• Landolfi R., De Cristofaro R., Castagnola M., De Candia E., D'Onofrio G., Leone G., Bizzi B. Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. Blood 1988; 71: 978–982
   PubMed Web of Science ®Google Scholar
• Moore A., Nachman R. L. Platelet Fc receptor: increased expression in myeloproliferative disease. J. Clin. Invest. 1981; 67: 1064–71
   PubMed Web of Science ®Google Scholar
• Walsh P. N., Murphy S., Barry W. E. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis. Thromb. Haemostas. 1977; 38: 1085–1096
   PubMed Web of Science ®Google Scholar
• Semeraro N., Cortelazzo S., Colucci M., Barbui T. A hitherto undescribed defect of platelet coagulant activity in polycythemia vera and essential thrombocythemia. Thromb. Res. 1979; 16: 795–802
   PubMed Web of Science ®Google Scholar
• Crook M., Marchin S. J., Crawford N. Basal and induced prothrombinase expression in platelets from patients with essential thrombocythemia (ET). Br. J. Haematol. 1990; 76: 256–259
   PubMed Web of Science ®Google Scholar
• Wilk A. S., Paulson O. B., Sorensen C. M. A study of 51Cr-labelled platelets and the chromosomal pattern in a case of primary haemorrhagic thrombocythemia. Acta. Haematol. 1971; 46: 177–187
   PubMed Web of Science ®Google Scholar
• Brodsky I., Kahn S. B., Ross E. M., Petkov G. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders. Cancer 1972; 30: 1444–1450
   PubMed Web of Science ®Google Scholar
• Kutti J., Ridell B., Weinfeld A., Westin J. The relation of thrombokinetics to bone marrow megacariocytes and to the size of the spleen in polycythemia vera. Scand. J. Haematol. 1973; 10: 88–95
   PubMedGoogle Scholar
• Berild D., Hasselbach H., Knudsen J. B. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders. Scand. J. Clin. Invest. 1987; 47: 497–501
   PubMed Web of Science ®Google Scholar
• van Genderen P. J. J., Michiels J. J., van Strik R., Lindemans J., van Vliet H. H. D.M. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb. Haemostas. 1995; 73: 210–214
   PubMed Web of Science ®Google Scholar